Drug Profile
Research programme: chimeric antigen receptor T cell therapy - HaemaLogiX
Alternative Names: CAR-T cell therapy - HaemaLogiX; LMA.CAR-TLatest Information Update: 22 Nov 2022
Price :
$50
*
At a glance
- Originator HaemaLogiX
- Developer HaemaLogiX; Westmead Institute for Medical Research
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Multiple myeloma
Most Recent Events
- 22 Nov 2022 Early research is underway for Multiple myeloma in Australia (HaemaLogiX pipeline, November 2022)
- 28 Oct 2019 No recent reports of development identified for early research development in Multiple-myeloma in Australia (Parenteral)
- 04 Jul 2018 HaemaLogiX and Takeda agree to co-develop therapeutics for the treatment of Multiple myeloma